| Title |
Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection
|
|---|---|
| Published in |
PLOS ONE, February 2010
|
| DOI | 10.1371/journal.pone.0009390 |
| Pubmed ID | |
| Authors |
Nancie M. Archin, Manzoor Cheema, Daniel Parker, Ann Wiegand, Ronald J. Bosch, John M. Coffin, Joseph Eron, Myron Cohen, David M. Margolis |
| Abstract |
Human immunodeficiency virus (HIV) infection that persists despite antiretroviral therapy (ART) is a daunting problem. Given the limited evidence that resting CD4+ T cell infection (RCI) is affected by the histone deacetylase (HDAC) inhibitor valproic acid (VPA), we measured the stability of RCI and residual viremia in patients who added VPA with or without raltegravir (RAL), or enfuvirtide (ENF) with or without VPA, to standard ART. |
Mendeley readers
The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 4% |
| Portugal | 1 | <1% |
| Australia | 1 | <1% |
| Argentina | 1 | <1% |
| Brazil | 1 | <1% |
| Spain | 1 | <1% |
| Denmark | 1 | <1% |
| Unknown | 101 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 31 | 28% |
| Researcher | 17 | 15% |
| Student > Master | 11 | 10% |
| Student > Bachelor | 8 | 7% |
| Other | 7 | 6% |
| Other | 21 | 19% |
| Unknown | 16 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 30% |
| Agricultural and Biological Sciences | 28 | 25% |
| Immunology and Microbiology | 12 | 11% |
| Biochemistry, Genetics and Molecular Biology | 6 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
| Other | 7 | 6% |
| Unknown | 21 | 19% |